{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:11:09Z","timestamp":1776424269447,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.jacl.2011.01.001","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T12:20:59Z","timestamp":1295007659000},"page":"91-96","source":"Crossref","is-referenced-by-count":57,"title":["The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort"],"prefix":"10.1016","volume":"5","author":[{"given":"Michel R.","family":"Hoenig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Gurnsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Beadle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.01.001_bib1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.01.001_bib2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FJC.0b013e3181f09bcb","article-title":"Markers of cholesterol absorption and synthesis predict the low density lipoprotein cholesterol response to atorvastatin","volume":"56","author":"Hoenig","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacl.2011.01.001_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2005.09.007","article-title":"Cholestanol: a serum marker to guide LDL cholesterol-lowering therapy","volume":"184","author":"Hoenig","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2011.01.001_bib4","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1023\/B:PHAM.0000029276.21063.0b","article-title":"Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)","volume":"21","author":"Pauli-Magnus","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.jacl.2011.01.001_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1023\/A:1011036428972","article-title":"HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein","volume":"18","author":"Wang","year":"2001","journal-title":"Pharm Res"},{"key":"10.1016\/j.jacl.2011.01.001_bib6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbapap.2009.02.014","article-title":"A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function","volume":"1794","author":"Fung","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2011.01.001_bib7","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.050585397","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2011.01.001_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/clpt.2008.25","article-title":"ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin","volume":"84","author":"Keskitalo","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2011.01.001_bib9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacl.2011.01.001_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.amjcard.2004.01.014","article-title":"Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner","volume":"93","author":"Kajinami","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.01.001_bib11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0169-409X(02)00064-9","article-title":"The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans","volume":"54","author":"Fromm","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jacl.2011.01.001_bib12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.01.001_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng1981","article-title":"A common coding variant in CASP8 is associated with breast cancer risk","volume":"39","author":"Cox","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacl.2011.01.001_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/CIRCGENETICS.108.818062","article-title":"Comprehensive whole genome and candidate gene analysis for response to statin therapy in TNT Cohort","volume":"2","author":"Thompson","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2011.01.001_bib15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/ajcn\/68.6.1215","article-title":"Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol","volume":"68","author":"Sarkkinen","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacl.2011.01.001_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1172\/JCI113107","article-title":"Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype","volume":"80","author":"Kesaniemi","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2011.01.001_bib17","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1194\/jlr.M300522-JLR200","article-title":"Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity","volume":"45","author":"Gylling","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2011.01.001_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1194\/jlr.M300278-JLR200","article-title":"ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin","volume":"45","author":"Kajinami","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2011.01.001_bib19","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.tpj.6500328","article-title":"An association study of 43 SNPs in 16 candidate genes with atorvastatin response","volume":"5","author":"Thompson","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jacl.2011.01.001_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2011.01.001_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2005.05.025","article-title":"The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia","volume":"185","author":"Bercovich","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2011.01.001_bib22","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.109.188474","article-title":"Identification of genetic variants associated with response to statin therapy","volume":"29","author":"Mega","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2011.01.001_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.bjp.0703920","article-title":"HMG-CoA reductase inhibitors and P-glycoprotein modulation","volume":"132","author":"Bogman","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacl.2011.01.001_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pds.1866","article-title":"Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy","volume":"19","author":"Becker","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacl.2011.01.001_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.01.001_bib26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T21:14:24Z","timestamp":1559942064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1933287411000171"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.01.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}